Corbus Pharmaceuticals Holdings, Inc. (CRBP) Director Acquires $34,500.00 in Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director David P. Hochman purchased 5,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were purchased at an average price of $6.90 per share, with a total value of $34,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded down $0.40 during midday trading on Tuesday, hitting $6.85. The stock had a trading volume of 883,300 shares, compared to its average volume of 811,852. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $5.30 and a 52 week high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The company had revenue of $0.80 million during the quarter. research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) Director Acquires $34,500.00 in Stock” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.themarketsdaily.com/2017/11/14/corbus-pharmaceuticals-holdings-inc-crbp-director-acquires-34500-00-in-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Corbus Pharmaceuticals Holdings by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 307,979 shares during the period. State Street Corp boosted its position in shares of Corbus Pharmaceuticals Holdings by 2,998.2% in the second quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 569,662 shares during the period. Northern Trust Corp boosted its position in shares of Corbus Pharmaceuticals Holdings by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after buying an additional 429,584 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Corbus Pharmaceuticals Holdings by 4.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 444,504 shares of the biopharmaceutical company’s stock worth $3,178,000 after buying an additional 18,224 shares during the period. Finally, Artal Group S.A. purchased a new stake in shares of Corbus Pharmaceuticals Holdings in the second quarter worth about $1,575,000. 29.20% of the stock is owned by institutional investors.

Several equities research analysts have commented on the company. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub lowered Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. ValuEngine lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Finally, Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $20.75.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply